Prevalence & Odds of Anxiety & Depression in Cutaneous Malignant Melanoma: A Proportional Meta-analysis & Regression
Garikai Kungwengwe,Chloe Gowthorpe,Stephen R Ali,Harry Warren,Damien J Drury,Ky-Leigh Ang,John A G Gibson,Thomas D Dobbs,Iain S Whitaker
DOI: https://doi.org/10.1093/bjd/ljae011
IF: 11.113
2024-01-10
British Journal of Dermatology
Abstract:Abstract Background The psychological burden of cutaneous malignant melanoma (CM) is all-encompassing, affecting treatment adherence, recurrence, and mortality. Yet, the prevalence and risk factors of anxiety and depression (A&D) in CM remain unclear. Objectives To establish a benchmark pooled prevalence of A&D in CM, provide magnitudes of association for clinical, therapeutic, and demographic correlates, and elucidate temporal trends in A&D from the time of diagnosis. Methods This review was reported in line with MOOSE guidance. MEDLINE, Embase, PsychINFO, Web of Science, and the Cochrane Library were queried from database inception through August 24th, 2023. Study selection, data extraction, and quality assessment were performed by two independent authors, utilising both the JBI and NIH risk of bias (ROB) tools for the latter. The GRADE approach was used to rate the certainty of evidence. Prevalence rates, 95% Confidence (CI), and Prediction (PI) Intervals were derived using a random-effects model, and estimating between- and within-study variance. Results Nine longitudinal and 29 cross-sectional studies were included (n = 7,995). Quality assessment revealed 20/17 low, 12/15 moderate, and six/five high ROB studies, based on JBI/NIH tools, respectively. The prevalence of A (30.6% [95% CI, 24.6-37.0%; PI, 18-47%]) and D (18.4% [95% CI, 13.4-23.9%; PI, 10-33%]) peaked during treatment, declining to pre-treatment levels after one year (A: 48% vs 20%, p = 0.005; D: 28% vs 13%, p = 0.03). Female gender (OR 1.8; 95% CI, 1.4-2.3; p < 0.001), age <60 years (OR 1.5; 95% CI, 1.2-2.0; p = 0.002), and low educational level (OR 1.5; 95% CI, 1.2-2.0; p < 0.001) were likely to result in a large increase in the odds of anxiety. Depression was 12.3% higher in stage IV vs I CM (p = 0.048). Relative to immune checkpoint inhibition, the rates of depression were 22% (p = 0.002) and 34% (p < 0.001) higher among advanced-stage patients receiving interferon-α and chemotherapy, respectively. A significant diminution in self-reported depression scores was demonstrated over time (p = 0.003). Conclusions A&D in CM notably affects women, under-60 s, and the less educated, with up to 80% higher odds of anxiety in these groups. A&D surge during CT & IFN treatment, especially in advanced CM. Our findings facilitate risk stratification and underscore the need for multi-disciplinary vigilance.
dermatology